Oxalic Acid

Oxalic Acid

SCHEMBL72932

O.O.O.O.O.O.O=C(O)C(=O)O.[Fe]

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

OPRM1SLC6A4

The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA9 Q16790 1/20 0.44
LDHA P00338 2/20 0.42
LDHB P07195 1/20 0.42
ACHE P22303 1/20 0.36
FFAR3 O14843 1/20 0.36
LCK P06239 1/20 0.36
FYN P06241 1/20 0.36
KDM5B Q9UGL1 1/20 0.36
OR51E2 Q9H255 1/20 0.33
TSHR P16473 2/20 0.31
EGLN1 Q9GZT9 2/20 0.31
SRR Q9GZT4 1/20 0.31
TP53 P04637 1/20 0.31
LMNA P02545 1/20 0.31
ALKBH5 Q6P6C2 1/20 0.31
SUCNR1 Q9BXA5 1/20 0.31
EGLN3 Q9H6Z9 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Oxalic Acid SCHEMBL222276 1.00
Oxalic Acid SCHEMBL27978033 1.00 CA1 (0.44) CA1CA2CA9LDHALDHB
Oxalic Acid SCHEMBL17203390 1.00 CA1 (0.44) CA1CA2CA9LDHALDHB
Oxalic Acid SCHEMBL2237747 1.00 CA1 (0.44) CA1CA2CA9LDHALDHB
Oxalic Acid SCHEMBL5163208 1.00 CA1 (0.44) CA1CA2CA9LDHALDHB
Oxalic Acid SCHEMBL284711 1.00
Oxalic Acid SCHEMBL9272707 1.00 CA1 (0.44) CA1CA2CA9LDHALDHB
Oxalic Acid SCHEMBL28708653 0.94 CA1 (0.40) CA1CA2CA9LDHALDHB
Oxalic Acid SCHEMBL1331097 0.94 CA1 (0.40) CA1CA2CA9LDHALDHB
Oxalic Acid SCHEMBL5398093 0.94

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120082281-A Preparation method of two-dimensional porous double transition metal oxide composite self-repairing noise-reducing anticorrosive coating 中国海洋大学 2025-06-03 CN claimed
CN-108892604-B Method for preparing halogenated benzo [ b ] fluorenone series compounds 江西师范大学 2022-05-31 CN claimed
US-11260369-B2 Catalytic composition, method of making and catalytic application thereof for producing ester(s) of glycerol BHARAT PETROLEUM CORPORATION LIMITED (IN) 2022-03-01 US claimed
CN-113563231-A Para C-H alkylated arylamine and preparation method thereof 黑龙江大学 2021-10-29 CN claimed
US-20210131201-A1 OIL SWELLABLE MATERIAL FOR LOW TEMPERATURE LOST CIRCULATION MATERIAL APPLICATION HALLIBURTON ENERGY SERVICES, INC. (US) 2021-05-06 US claimed
WO-2021086416-A1 OIL SWELLABLE MATERIAL FOR LOW TEMPERATURE LOST CIRCULATION MATERIAL APPLICATION HALLIBURTON ENERGY SERVICES, INC. (US) 2021-05-06 WO claimed
CN-110003061-B Method for direct amination of methyl aromatic compound benzyl hydrocarbon under catalysis of iron 河南农业大学 2021-04-02 CN claimed
EP-3274298-B1 METHOD FOR PREPARING A CATALYST AND METHOD FOR GREEN BIODIESEL PRODUCTION FROM UNREFINED LOW GRADE FEEDSTOCK UNIV HONG KONG POLYTECHNIC (CN) 2019-10-09 EP claimed
US-10100132-B2 Process for the preparation of polymers containing amino groups employing a heterogeneous iron catalyst ARLANXEO DEUTSCHLAND GMBH (US) 2018-10-16 US claimed
US-9694350-B2 Methods and catalysts for green biodiesel production from unrefined low grade feedstock THE HONG KONG POLYTECHNIC UNIVERSITY (CN) 2017-07-04 US claimed
US-20170081430-A1 PROCESS FOR THE PREPARATION OF POLYMERS CONTAINING AMINO GROUPS EMPLOYING A HETEROGENEOUS IRON CATALYST ARLANXEO DEUTSCHLAND GMBH (DE) 2017-03-23 US claimed
US-20160279616-A1 METHODS AND CATALYSTS FOR GREEN BIODIESEL PRODUCTION FROM UNREFINED LOW GRADE FEEDSTOCK THE HONG KONG POLYTECHNIC UNIVERSITY (HK) 2016-09-29 US claimed
US-20120318510-A1 METHODS OF GENERATING MAGNETIC PARTICLES IN A SUBTERRANEAN ENVIRONMENT SCHLUMBERGER TECHNOLOGY CORPORATION (US) 2012-12-20 US claimed
US-7892520-B2 grinding hydrated iron salts, inorganic salts and alkali hydroxides, then heat treating the mixture to form hematite nanostructure particles, used as magnetic resonance image contrast agents, inks, artificial tanning pigments, photocatalysts, red pigments, water treatment adsorbents or catalyst supports THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) 2011-02-22 US claimed
US-20080181843-A1 Solid-state synthesis of iron oxide nanoparticles THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) 2008-07-31 US claimed
EP-4649086-A1 PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION Merck Sharp & Dohme LLC (US) 2025-11-19 EP disclosed
US-12377100-B2 Toll like receptor modulator compounds GILEAD SCIENCES, INC. (US) 2025-08-05 US disclosed
US-20080181843-A1 Solid-state synthesis of iron oxide nanoparticles THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) 2008-07-31 US disclosed
EP-1704057-A1 LASER IMAGING Sherwood Technology LTD. (GB) 2006-09-27 EP disclosed
WO-2005068207-A1 LASER IMAGING DATALASE LTD. (GB) 2005-07-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12377100-B2 Toll like receptor modulator compounds TLR8, TLR3, TLR6 CA1 4871/4885CA2 4092/4885CA9 4780/4885
US-11260369-B2 Catalytic composition, method of making and catalytic application thereof for producing ester(s) of glycerol MGLL, AGL, GK CA1 662/4885CA2 643/4885CA9 277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.